A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease

Trial Profile

A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Mardepodect (Primary)
  • Indications Huntington's disease
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Oct 2016 Status changed from recruiting to completed.
    • 27 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016.
    • 10 Aug 2016 Planned End Date changed from 1 Oct 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top